INT3230

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1978
Last Reported 2003
Negated 1
Speculated 0
Reported most in Abstract
Documents 9
Total Number 9
Disease Relevance 1.85
Pain Relevance 4.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Prl)
Anatomy Link Frequency
plasma 4
pituitary 2
Prl (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 23 100.00 Very High Very High Very High
Dopamine 22 100.00 Very High Very High Very High
noradrenaline 8 100.00 Very High Very High Very High
agonist 18 98.58 Very High Very High Very High
Clonidine 8 98.32 Very High Very High Very High
fortral 1 97.82 Very High Very High Very High
dopamine receptor 5 93.72 High High
opiate 3 93.12 High High
narcan 4 91.68 High High
Calcium channel 2 87.48 High High
Disease Link Frequency Relevance Heat
Cancer 3 100.00 Very High Very High Very High
Antisocial Personality Disorder 7 99.84 Very High Very High Very High
Prolactinoma 2 96.96 Very High Very High Very High
Stress 4 93.92 High High
Cluster Headache 1 86.96 High High
Headache 2 82.08 Quite High
Pituitary Cancer 1 66.76 Quite High
Galactorrhea 1 64.84 Quite High
Multiple Endocrine Neoplasia 1 61.76 Quite High
Reprotox - General 1 1 59.24 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The administration of pimozide, a dopamine antagonist, increased plasma PRL and completely prevented the restraint-induced decrease in PRL.
Negative_regulation (prevented) of Negative_regulation (decrease) of PRL in plasma associated with dopamine and antagonist
1) Confidence 0.43 Published 1986 Journal Neuroendocrinology Section Abstract Doc Link 3724981 Disease Relevance 0.35 Pain Relevance 0.67
This case illustrates that during dopamine agonist therapy a discrepancy may exist in the clinical response as judged by reduction in tumour size and decrease in the circulating prolactin level.
Negative_regulation (reduction) of Negative_regulation (decrease) of prolactin associated with dopamine, cancer and agonist
2) Confidence 0.42 Published 1986 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 3742834 Disease Relevance 0.80 Pain Relevance 0.40
Furthermore pimozide did not attenuate the inhibition of clonidine-induced GH secretion seen after apomorphine administration, however, it completely reversed apomorphine-induced PRL inhibition.
Negative_regulation (reversed) of Negative_regulation (inhibition) of PRL associated with clonidine
3) Confidence 0.42 Published 1978 Journal Horm. Res. Section Abstract Doc Link 669571 Disease Relevance 0 Pain Relevance 0.42
Gamma-Endorphin did not affect the prolactin secretion by hemipituitary glands incubated in vitro and by cultured pituitary cells, but it reversed, in a dose-dependent way, the dopamine-induced inhibition of prolactin release.
Negative_regulation (reversed) of Negative_regulation (inhibition) of prolactin in pituitary associated with dopamine
4) Confidence 0.41 Published 1982 Journal Neuropharmacology Section Abstract Doc Link 6184642 Disease Relevance 0 Pain Relevance 0.52
Flunarizine treatment increased basal prolactin levels, but it did not reduce the inhibitory response of prolactin to acute bromocriptine administration.
Neg (not) Negative_regulation (reduce) of Negative_regulation (response) of prolactin
5) Confidence 0.34 Published 1997 Journal Clin Neuropharmacol Section Abstract Doc Link 9197946 Disease Relevance 0.17 Pain Relevance 0.31
DA receptors sensitivity seems to be reduced significantly in ASPD (A subjects); in contrast, heroin addicts without open psychiatric co-morbidity showed unimpaired responses to brom challenge; a significantly lower GH response to brom and a lack of PRL suppression in ASPD subjects could express D2 postsynaptic receptor hyposensitivity possibly related to DA gene variants associated to co-morbid disorder.
Negative_regulation (lack) of Negative_regulation (suppression) of PRL associated with dopamine and antisocial personality disorder
6) Confidence 0.33 Published 2003 Journal Addict Biol Section Abstract Doc Link 12745412 Disease Relevance 0.54 Pain Relevance 0.35
In this system, sulpiride (100 nM), a dopamine D2 antagonist, reversed the prolactin inhibition produced by lisuride (20 nM).
Negative_regulation (reversed) of Negative_regulation (inhibition) of prolactin associated with dopamine and antagonist
7) Confidence 0.31 Published 1991 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1676676 Disease Relevance 0 Pain Relevance 0.69
The in-vitro prolactin release-inhibiting effect of noradrenaline (10-7 mol/l) was not blocked by the dopamine antagonists pimozide (D2) or SCH23390 (D1) but was blocked by each of the adrenoceptor antagonists (alpha1-adrenoceptor antagonists prazosin and WB4101, the alpha2-adrenoceptor antagonist yohimbine and the beta-adrenoceptor antagonist propranolol).
Negative_regulation (blocked) of Negative_regulation (release-inhibiting) of prolactin associated with dopamine, antagonist and noradrenaline
8) Confidence 0.22 Published 2000 Journal J. Neuroendocrinol. Section Abstract Doc Link 10718926 Disease Relevance 0 Pain Relevance 0.91
Pretreatment with a 'putative' sigma receptor agonist, pentazocine, prevented the rimcazole-induced increase of the concentration of DOPAC in the median eminence, but did not block the ability of rimcazole to decrease plasma concentrations of prolactin.
Negative_regulation (block) of Negative_regulation (decrease) of prolactin in plasma associated with fortral and agonist
9) Confidence 0.09 Published 1996 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8901020 Disease Relevance 0 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox